| Literature DB >> 32376874 |
Federico Pietrocola1, Guido Kroemer2,3,4,5,6, Francesca Castoldi7,8, Mervi T Hyvönen9, Sylvère Durand8, Fanny Aprahamian8, Allan Sauvat7,8, Shoaib A Malik7,8,10, Elisa Elena Baracco7,8, Erika Vacchelli7,8, Paule Opolon11, Nicolas Signolle11, Déborah Lefevre8, Noelie Bossut8, Tobias Eisenberg12,13,14, Christopher Dammbrueck12,13,14, Tobias Pendl12,13,14, Margerie Kremer7,8, Sylvie Lachkar7,8, Claudia Einer15, Bernhard Michalke16, Hans Zischka15,17, Frank Madeo12,13,14, Tuomo A Keinänen9, Maria Chiara Maiuri7,8.
Abstract
The pharmacological targeting of polyamine metabolism is currently under the spotlight for its potential in the prevention and treatment of several age-associated disorders. Here, we report the finding that triethylenetetramine dihydrochloride (TETA), a copper-chelator agent that can be safely administered to patients for the long-term treatment of Wilson disease, exerts therapeutic benefits in animals challenged with hypercaloric dietary regimens. TETA reduced obesity induced by high-fat diet, excessive sucrose intake, or leptin deficiency, as it reduced glucose intolerance and hepatosteatosis, but induced autophagy. Mechanistically, these effects did not involve the depletion of copper from plasma or internal organs. Rather, the TETA effects relied on the activation of an energy-consuming polyamine catabolism, secondary to the stabilization of spermidine/spermine N1-acetyltransferase-1 (SAT1) by TETA, resulting in enhanced enzymatic activity of SAT. All the positive effects of TETA on high-fat diet-induced metabolic syndrome were lost in SAT1-deficient mice. Altogether, these results suggest novel health-promoting effects of TETA that might be taken advantage of for the prevention or treatment of obesity.Entities:
Year: 2020 PMID: 32376874 PMCID: PMC7494776 DOI: 10.1038/s41418-020-0550-z
Source DB: PubMed Journal: Cell Death Differ ISSN: 1350-9047 Impact factor: 15.828